The role of NKT cells in gastrointestinal cancers
Authors:
Open Access
- 30 December 2021
- journal article
- other
- Published by Taylor & Francis in OncoImmunology
- Vol. 11 (1) , 2009666
Abstract
Gastrointestinal (GI) cancers represent a complex array of cancers that affect the digestive system. This includes liver, pancreatic, colon, rectal, anal, gastric, esophageal, intestinal and gallbladder cancer. Patients diagnosed with certain GI cancers typically have low survival rates, so new therapeutic approaches are needed. A potential approach is to harness the potent immunoregulatory properties of natural killer T (NKT) cells which are true T cells, not natural killer (NK) cells, that recognize lipid instead of peptide antigens presented by the non-classical major histocompatibility (MHC) molecule CD1d. The NKT cell subpopulation is known to play a vital role in tumor immunity by bridging innate and adaptive immune responses. In GI cancers, NKT cells can contribute to either antitumor or protumor immunity depending on the cytokine profile expressed and type of cancer. This review discusses the complexities of the role of NKT cells in liver, colon, pancreatic and gastric cancers with an emphasis on type I NKT cells.Keywords
Funding Information
- Intramural Research of the NIH, National Cancer Institute (ZIA-C-004020)
This publication has 91 references indexed in Scilit:
- Combination of Intratumoral Invariant Natural Killer T Cells and Interferon-Gamma Is Associated with Prognosis of Hepatocellular Carcinoma after Curative ResectionPLOS ONE, 2013
- Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cellsProceedings of the National Academy of Sciences, 2013
- IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activityJournal of Clinical Investigation, 2012
- Role of Natural Killer T Cells in the Mouse Colitis‐Associated Colon Cancer ModelScandinavian Journal of Immunology, 2011
- Mouse and human iNKT cell agonist β-mannosylceramide reveals a distinct mechanism of tumor immunityJournal of Clinical Investigation, 2011
- Antigen-Specific Cytotoxicity by Invariant NKT Cells In Vivo Is CD95/CD178-Dependent and Is Correlated with Antigenic PotencyThe Journal of Immunology, 2010
- Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophagesJournal of Clinical Investigation, 2009
- Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphomaBlood, 2008
- Restoration of Tumor Immunosurveillance via Targeting of Interleukin-13 Receptor-α2Cancer Research, 2008
- Chapter 8 The Role of NKT Cells in Tumor Immunity2008